This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2014 Jul;44(1):239-41.

doi: 10.1183/09031936.00220413. Epub 2014 Mar 23.

The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia

Hector Ortega¹, Geoffrey Chupp², Philip Bardin³, Arnaud Bourdin⁴, Gilles Garcia⁵, Benjamin Hartley⁶, Steve Yancey⁷, Marc Humbert⁸

Affiliations

Affiliations

¹ GlaxoSmithKline, Respiratory Medicine Development Center, Research Triangle Park, NC, USA hector.g.ortega@gsk.com.
² Dept of Pulmonary and Critical Care, Yale University Medical School, Winchester Chest Clinic, 20 York Street, New Haven, CT, USA.
³ Monash University and Medical Centre, Lung and Sleep, Melbourne, Australia.
⁴ Dept of Allergy, Hospital Arnaud de Villeneuve, Montpellier, France.
⁵ University Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France AP-HP, Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
⁶ GlaxoSmithKline, Research and Development, Stockley Park, Middlesex, UK.
⁷ GlaxoSmithKline, Respiratory Medicine Development Center, Research Triangle Park, NC, USA.
⁸ University Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France AP-HP, Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France Inserm U999, LabEx LERMIT, Le Plessis Robinson, France.

PMID: 24659543
DOI: 10.1183/09031936.00220413

Free article

The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia

Hector Ortega et al. Eur Respir J. 2014 Jul.

Free article

. 2014 Jul;44(1):239-41.

doi: 10.1183/09031936.00220413. Epub 2014 Mar 23.

Authors

Hector Ortega¹, Geoffrey Chupp², Philip Bardin³, Arnaud Bourdin⁴, Gilles Garcia⁵, Benjamin Hartley⁶, Steve Yancey⁷, Marc Humbert⁸

Affiliations

¹ GlaxoSmithKline, Respiratory Medicine Development Center, Research Triangle Park, NC, USA hector.g.ortega@gsk.com.
² Dept of Pulmonary and Critical Care, Yale University Medical School, Winchester Chest Clinic, 20 York Street, New Haven, CT, USA.
³ Monash University and Medical Centre, Lung and Sleep, Melbourne, Australia.
⁴ Dept of Allergy, Hospital Arnaud de Villeneuve, Montpellier, France.
⁵ University Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France AP-HP, Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
⁶ GlaxoSmithKline, Research and Development, Stockley Park, Middlesex, UK.
⁷ GlaxoSmithKline, Respiratory Medicine Development Center, Research Triangle Park, NC, USA.
⁸ University Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France AP-HP, Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France Inserm U999, LabEx LERMIT, Le Plessis Robinson, France.

PMID: 24659543
DOI: 10.1183/09031936.00220413

No abstract available

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information